A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 10,552 shares of ABCL stock, worth $30,811. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,552
Previous 11,735 10.08%
Holding current value
$30,811
Previous $34,000 20.59%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$2.39 - $3.49 $2,827 - $4,128
-1,183 Reduced 10.08%
10,552 $27,000
Q2 2024

Jul 19, 2024

BUY
$2.73 - $4.73 $819 - $1,419
300 Added 2.62%
11,735 $34,000
Q1 2024

Apr 22, 2024

BUY
$4.29 - $5.97 $2,145 - $2,985
500 Added 4.57%
11,435 $51,000
Q4 2023

Jan 16, 2024

BUY
$3.91 - $5.93 $42,755 - $64,844
10,935 New
10,935 $62,000

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $833M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.